Lumakras Can Trigger ILD. New Findings Suggest Why

Lumakras (sotorasib) is a cancer drug that has been approved for the treatment of non-small cell lung cancer harboring the KRAS G12C mutation. Over the past few years, it has shown clear clinical benefits. Still, its use has been hampered by…